The UK’s psychedelic sector is moving into a more commercially significant phase, with late-stage clinical programmes, pharmaceutical investment and changes to the country’s clinical-trial system beginning to reshape an industry that was once dominated by academic research. Several of the developments attracting attention in 2026 are not British companies or British trials. But they reflect […]
Already subscribed? Log in
US-listed BioAdaptives, Inc. (OTCID: BDPT) has signed a definitive agreement to acquire Xycota Biosciences LLC, a privately held biotechnology company developing experimental psychedelic medicines for psychiatric and neurological...
Canadian biotechnology company PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) has signed an agreement with Corealis Pharma Inc., a contract development and manufacturing organisation based in Laval,...
Definium Therapeutics (NASDAQ: DFTX) is set to present findings from three positive Phase 3 clinical trials of its LSD-based drug candidate, DT120 ODT, at the 2026 Neuroscience Education...
New preclinical findings suggest EB-003 can alter brain activity without producing some of the adverse neurological effects observed with DMT in mice. Enveric Biosciences (NASDAQ: ENVB) has reported...
Psychedelics.media delivers trusted news, intelligence, and insights for the global psychedelic medicine industry.
